Analysis of a rare melanoma patient with a spontaneous CTL response to a MAGE-A3 peptide presented by HLA-A1
- 26 September 2005
- journal article
- case report
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 55 (2) , 178-184
Abstract
We describe an HLA-A1 melanoma patient who has mounted a spontaneous cytolytic T cell (CTL) response against an antigenic peptide encoded by gene MAGE-A3 and presented by HLA-A1. The frequency of anti-MAGE-3.A1 CTLp was 5 x 10(-7) of the blood CD8 cells, with a dominant clonotype which was present in six out of seven independent anti-MAGE-3.A1 CTL clones. After vaccination with a recombinant poxvirus coding for the MAGE-3.A1 antigen, the blood frequency of anti-MAGE-3.A1 CTLp increased tenfold. Twenty-two independent CTL clones were derived. Surprisingly, only one of them corresponded to the dominant clonotype present before vaccination. Two new clonotypes were repeated 12 and 7 times, respectively. Our interpretation of these results is that the spontaneous anti-MAGE-3.A1 CTL response pre-existing to vaccination was polyclonal, and that the vaccine restimulated only some of these clones. To estimate the incidence of spontaneous anti-MAGE-3.A1 CTL responses in melanoma patients with a tumor expressing gene MAGE-A3, we measured the blood frequency of anti-MAGE-3.A1 T cells in 45 patients, and found only two clear responses.Keywords
This publication has 12 references indexed in Scilit:
- Tumoral and Immunologic Response After Vaccination of Melanoma Patients With an ALVAC Virus Encoding MAGE Antigens Recognized by T CellsJournal of Clinical Oncology, 2005
- Correlation between tumor regression and T cell responses in melanoma patients vaccinated with a MAGE antigenProceedings of the National Academy of Sciences, 2004
- Monoclonal Anti-MAGE-3 CTL Responses in Melanoma Patients Displaying Tumor Regression after Vaccination with a Recombinant Canarypox VirusThe Journal of Immunology, 2003
- A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by geneMAGE-3Proceedings of the National Academy of Sciences, 2001
- Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by geneMAGE-3 and presented by HLA-A1International Journal of Cancer, 1999
- LAGE-1, a new gene with tumor specificityInternational Journal of Cancer, 1998
- A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screeningProceedings of the National Academy of Sciences, 1997
- Applications of pox virus vectors to vaccination: an update.Proceedings of the National Academy of Sciences, 1996
- BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytesImmunity, 1995
- Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes.Journal of Experimental Medicine, 1994